Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2026)

Coherus Oncology has disclosed Other Operating Expenses across 8 years of filings, most recently posting $3.8 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $3.8 million, up 43.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (up 50.64% YoY), and the FY2025 annual result was $13.8 million, up 58.29% from the prior year.
• Other Operating Expenses came in at $3.8 million for Q1 2026 at Coherus Oncology, down from $4.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $24.8 million in Q2 2023 to a low of -$108.5 million in Q3 2022.
• The 5-year median for Other Operating Expenses is $2.8 million (2024), against an average of -$13.4 million.
• Across the five-year window, Other Operating Expenses sank 745.25% in 2022 and surged 120.34% in 2023, its largest moves.
• Coherus Oncology's Other Operating Expenses stood at -$78.1 million in 2022, then slipped by 1.99% to -$79.7 million in 2023, then surged by 103.45% to $2.8 million in 2024, then jumped by 47.09% to $4.0 million in 2025, then declined by 5.71% to $3.8 million in 2026.
• The last three Other Operating Expenses figures came in at $3.8 million (Q1 2026), $4.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.